<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): October 23, 2008</B>

<P style="font-size: 24pt" align="center"><B>BioCryst Pharmaceuticals,
Inc.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-23186</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>62-1413174</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>2190 Parkway Lake Drive, <BR>
Birmingham, Alabama <BR></B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>35244</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(205) 444-4600</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD nowrap align="left" width="3%"><B>Item&nbsp;5.02</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify"><B>Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.</B></DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="justify">On October&nbsp;23, 2008, Michael A.
Darwin, the Vice President of Finance and Principal Accounting Officer of
BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;), tendered his
resignation from employment with the Company, effective December 31, 2008. The
company will provide eight months of severance pay and twelve months of paid
COBRA. In addition, beginning on December&nbsp;31, 2008 Mr.&nbsp;Darwin will be
provided with a six month consulting agreement to provide the Company with
certain financial and SEC regulation support.<I>&nbsp; </I>Under this
consulting agreement he will be paid five hundred dollars ($500) per month for
such services.

<P style="font-size: 10pt" align="justify">As a result of this change, the
Company has appointed J. Michael Mills, 34, as the Principal Accounting Officer
effective December&nbsp;31, 2008. Mr.&nbsp;Mills has served as Controller of
the Company since January&nbsp;2005. Prior to joining the Company,
Mr.&nbsp;Mills served as a Division Controller with Compass Bank from
September&nbsp;2003 to January&nbsp;2005. Mr.&nbsp;Mills began his career with
Ernst &amp; Young in September&nbsp;1997 and served as Manager from
October&nbsp;2002 to August&nbsp;2003.

<P style="font-size: 10pt; margin-right: 4%" align="justify">There are no
family relationships between Mr.&nbsp;Mills and any director or executive
officer of the Company.

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="justify">Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="45%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="50%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD nowrap align="left">Dated: October 24, 2008</TD>

  <TD nowrap align="left" colspan="2"><B>BioCryst Pharmaceuticals, Inc.</B></TD>
 </TR><!-- End Table Head -->
<!-- Begin Table Body -->

 <TR><TD>&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>By:&nbsp;</TD>
  <TD valign="top" align="left" style="border-bottom: 1px solid #000000"> /s/ Alane Barnes</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Alane Barnes</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">General Counsel, Corporate Secretary</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c76315e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 8028}]
{"company-data": {"conformed-name": "BIOCRYST PHARMACEUTICALS INC", "cik": "0000882796", "assigned-sic": "2836", "irs-number": "621413174", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-23186", "film-number": "081138700"}, "business-address": {"street1": "2190 PARKWAY LAKE DR", "city": "BIRMINGHAM", "state": "AL", "zip": "35244", "phone": "2054444600"}, "mail-address": {"street1": "2190 PARKWAY LAKE DR", "city": "BIRMINGHAM", "state": "AL", "zip": "35244"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): October 23, 2008
BioCryst Pharmaceuticals,
Inc.
(Exact name of registrant as
specified in its charter)
Delaware
000-23186
62-1413174
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2190 Parkway Lake Drive,
Birmingham, Alabama
35244
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(205) 444-4600
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On October 23, 2008, Michael A.
Darwin, the Vice President of Finance and Principal Accounting Officer of
BioCryst Pharmaceuticals, Inc. (the "Company"), tendered his
resignation from employment with the Company, effective December 31, 2008. The
company will provide eight months of severance pay and twelve months of paid
COBRA. In addition, beginning on December 31, 2008 Mr. Darwin will be
provided with a six month consulting agreement to provide the Company with
certain financial and SEC regulation support.
Under this
consulting agreement he will be paid five hundred dollars ($500) per month for
such services.
As a result of this change, the
Company has appointed J. Michael Mills, 34, as the Principal Accounting Officer
effective December 31, 2008. Mr. Mills has served as Controller of
the Company since January 2005. Prior to joining the Company,
Mr. Mills served as a Division Controller with Compass Bank from
September 2003 to January 2005. Mr. Mills began his career with
Ernst & Young in September 1997 and served as Manager from
October 2002 to August 2003.
There are no
family relationships between Mr. Mills and any director or executive
officer of the Company.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 24, 2008
BioCryst Pharmaceuticals, Inc.
By:
/s/ Alane Barnes
Alane Barnes
General Counsel, Corporate Secretary